Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628383 | 1.00 | GSK3B (0.57) | GSK3BPTPN1MAPTALDH1A1PKM | |
| SCHEMBL5054876 | 0.85 | GSK3B (0.57) | GSK3BPTPN1 | |
| SCHEMBL12609858 | 0.85 | GSK3B (0.53) | GSK3BMAPTALDH1A1PKMMEN1 | |
| SCHEMBL747174 | 0.84 | GSK3B (0.61) | GSK3BPTPN1 | |
| SCHEMBL29514695 | 0.84 | GSK3B (0.61) | GSK3BPTPN1 | |
| SCHEMBL4889600 | 0.83 | MAPT (0.49) | MAPTALDH1A1PKMMEN1LMNA | |
| Bromide SCHEMBL5722043 | 0.82 | GSK3B (0.59) | GSK3BPTPN1 | |
| SCHEMBL3995406 | 0.82 | GSK3B (0.59) | GSK3BPTPN1 | |
| SCHEMBL6514586 | 0.81 | GSK3B (0.57) | GSK3BPTPN1LMNA | |
| SCHEMBL11736603 | 0.80 | KMT2A (0.49) | MAPTALDH1A1PKMMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-04 | — | — | US | disclosed |
| CN-114096545-A | Novel heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| EP-2688870-B1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-8802673-B2 | Heterocyclic amine derivatives | Hoffmann-La Roche Inc (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2688870-A1 | HETEROCYCLIC AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| WO-2013144224-A1 | ACETYLENIC MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144224-A1 | ACETYLENIC MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-03 | — | — | WO | disclosed |
| EP-2299824-B1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012126922-A1 | HETEROCYCLIC AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
| US-20110144056-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-06-16 | — | — | US | disclosed |
| US-20110144056-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-06-16 | — | — | US | disclosed |
| WO-2009151991-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP1A2 | GSK3B 3292/4885PTPN1 3505/4885MAPT 3488/4885 |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | TAAR1, TAAR5, MTNR1A | GSK3B 783/4885PTPN1 1373/4885MAPT 353/4885 |
| US-20110144056-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, HRH2 | GSK3B 1981/4885PTPN1 4070/4885MAPT 878/4885 |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | ALK, ERBB2, ABL1 | GSK3B 772/4885PTPN1 1011/4885MAPT 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.